Development and validation of RP-HPLC/UV methods for the estimation of Risedronate sodium in pure and pharmaceutical dosage form

Subramaniam, A. T.; Velmurugan, D.; Ramanathan, S.; Dhanabalan, K.; Munusamy, J.; Gampala, H. Development and Validation of RP-HPLC UV Methods for the Estimation of Risedronate Sodium in Pure and Pharmaceutical Dosage Form. J Pharm Chem 2021, 6 (1). https://doi.org/10.14805/jphchem.2019.art112.

Abstract

Recent study was conducted to develop and validate analytical methods for estimation of Risedronate sodium in pure and pharmaceutical dosage form using UV Spectroscopy and RP- HPLC method. The first method (Method A) based on the UV Spectroscopy using 0.1 M HCl as diluent Lambda_max was found at 261 nm. Linearity existed perceived in the concentration between 10-50 µg/mL (r² = 0.999) for the method. The method was validated pertaining to linearity, precision and accuracy studies, LOD and LOQ consistent with ICH guidelines. The second method (Method B), based on determination of Risedronate sodium tablet dosage form by RP-HPLC method. Chromatography separation was carried out on a C₁₈(150X4.6 mm x 5 µ) SS Column using Methanol: Ammonium formate (85:15) as the mobile phase at a flow rate of 1.0 mL/min. The chromatographic analysis was carried out in the reflectance and absorbance mode at 254 nm and retention time of the drug was found to be 1.11 mL/min for standard and tablet. Linear responses of the drug were in the concentration range of 200-1000 µg/mL. The accuracy of the method was assessed by standard dilution method and found to be 98% to 102% .The results of the analysis were validated statistically prism software. The method established was found to be simple, precise, linear, accurate and sensitive. The developed method can be used for routine quality control analysis of Risedronate sodium in pure and pharmaceutical dosage form.

PDF

References

European Pharmacopoeia. 4 ed.; (EDQM), E. D. f. Q. o. M., Ed. European Council: Strasbourg, 2002, pp 1661-1662.

Indian Pharmacopoeia. (IPC), I. P. C., Ed. Government of India: Ghaziabad, 1996, pp 2789-2791.

Crandall, C. Risedronate: A Clinical Review. Arch Intern Med 2001, 161 (3), 353-360.

https://doi.org/10.1001/archinte.161.3.353

Brezovska, K.; Dimitrovska, A.; Kitanovski, Z.; Petrusevska, J.; Ribarska, J. T.; Jolevska, S. T. Development of an Ion-Pair Reversed-Phase HPLC Method with Indirect UV Detection for Determination of Phosphates and Phosphites as Impurities in Sodium Risedronate. J AOAC Int 2010, 93 (4), 1113-1120.

Vallano, P. T.; Shugarts, S. B.; Kline, W. F.; Woolf, E. J.; Matuszewski, B. K. Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B 2003, 794 (1), 23-33.

https://doi.org/10.1016/S1570-0232(03)00394-5

Ghassabian, S.; Wright, L. A.; deJager, A. D.; Smith, M. T. Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. Journal of Chromatography B 2012, 881-882, 34-41.

https://doi.org/10.1016/j.jchromb.2011.11.031

Walash, M. I.; Metwally, M. E. S.; Eid, M.; El-Shaheny, R. N. Spectrophotometric Determination of Risedronate in Pharmaceutical Formulations via Complex Formation with Cu (II) Ions: Application to Content Uniformity Testing. International journal of biomedical science : IJBS 2008, 4 (4), 303-309.

Walash, M. I.; Metwally, M. E. S.; Eid, M. I.; El-Shaheny, R. N. Spectrophotometric Determination of Risedronate and Etidronate in Pharmaceutical Formulations via the Molybdovanadate Method. Anal Lett 2009, 42 (11), 1571-1587.

https://doi.org/10.1080/00032710902993795

Committee, I. C. H. S., ICH Q2A Text on Validation of Analytical Procedures (CPMP/ICH/381/95). European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation: London, 1994.